LU91405I2 - "Lawsonia intracellularis et ses dérivés pharmaceutiquement acceptables (Enterisol Ileitis)" - Google Patents

"Lawsonia intracellularis et ses dérivés pharmaceutiquement acceptables (Enterisol Ileitis)"

Info

Publication number
LU91405I2
LU91405I2 LU91405C LU91405C LU91405I2 LU 91405 I2 LU91405 I2 LU 91405I2 LU 91405 C LU91405 C LU 91405C LU 91405 C LU91405 C LU 91405C LU 91405 I2 LU91405 I2 LU 91405I2
Authority
LU
Luxembourg
Prior art keywords
pharmaceutically acceptable
acceptable derivatives
lawsonia intracellularis
enterisol ileitis
enterisol
Prior art date
Application number
LU91405C
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27041284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91405(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/465,337 external-priority patent/US5714375A/en
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of LU91405I2 publication Critical patent/LU91405I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C12N9/92—Glucose isomerase (5.3.1.5; 5.3.1.9; 5.3.1.18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56922—Campylobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
LU91405C 1995-06-05 2007-12-21 "Lawsonia intracellularis et ses dérivés pharmaceutiquement acceptables (Enterisol Ileitis)" LU91405I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/465,337 US5714375A (en) 1995-06-05 1995-06-05 Ileal symbiont intracellularis propagation in suspended host cells
US08/658,194 US5885823A (en) 1995-06-05 1996-06-04 Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
EP03022895.1A EP1403643B2 (fr) 1995-06-05 1996-06-05 Cultivation de Lawsonia intracellularis, vaccins anti-lawsonia et agents de diagnostique
EP96921391.7A EP0843818B2 (fr) 1995-06-05 1996-06-05 Culture de lawsonia intracellularis, vaccin contre lawsonia intracellularis et agents de diagnostic

Publications (1)

Publication Number Publication Date
LU91405I2 true LU91405I2 (fr) 2008-02-21

Family

ID=27041284

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91405C LU91405I2 (fr) 1995-06-05 2007-12-21 "Lawsonia intracellularis et ses dérivés pharmaceutiquement acceptables (Enterisol Ileitis)"

Country Status (23)

Country Link
US (1) US5885823A (fr)
EP (5) EP1403643B2 (fr)
JP (4) JP3765834B2 (fr)
KR (4) KR100544857B1 (fr)
AT (3) ATE289069T1 (fr)
AU (1) AU717045B2 (fr)
BG (1) BG64292B1 (fr)
BR (2) BR9608338B1 (fr)
CA (1) CA2222643C (fr)
CZ (1) CZ295933B6 (fr)
DE (5) DE843818T1 (fr)
DK (3) DK1403643T3 (fr)
ES (3) ES2294620T5 (fr)
FR (1) FR07C0071I2 (fr)
HU (1) HU230199B1 (fr)
LU (1) LU91405I2 (fr)
NL (1) NL300331I2 (fr)
NZ (1) NZ319994A (fr)
PL (6) PL187850B1 (fr)
PT (3) PT1645567E (fr)
RO (1) RO118885B1 (fr)
RU (2) RU2265849C2 (fr)
WO (1) WO1996039629A1 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022328B1 (en) 1995-11-30 2006-04-04 Australian Pork Limited Therapeutic and diagnostic compositions
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US7029683B1 (en) 1999-05-13 2006-04-18 Pfizer Products, Inc. Lawsonia derived gene and related hemolysin polypeptides, peptides and proteins and their uses
EP1177213A4 (fr) * 1999-05-13 2002-08-28 Pfizer Prod Inc Gene derive de lawsonia, polypeptides, peptides et proteines d'hemolysine et leurs utilisations
WO2000069905A1 (fr) * 1999-05-13 2000-11-23 Australian Pork Limited Gene derive de $i(lawsonia)et polypeptides, peptides et proteines omph apparentes, et leurs utilisations
WO2000069903A1 (fr) * 1999-05-13 2000-11-23 Pfizer Products Inc Gene derive de $i(lawsonia) et polypeptides, peptides et proteines sodc associes, et leurs utilisations
AU771376B2 (en) * 1999-05-13 2004-03-18 Agriculture Victoria Services Pty Ltd Lawsonia derived gene and related FlgE polypeptides, peptides and proteins and their uses
US7052697B1 (en) * 1999-05-13 2006-05-30 Agriculture Victoria Services Pty Ltd Lawsonia derived gene and related OmpH polypeptides, peptides and proteins and their uses
US6605696B1 (en) * 1999-10-22 2003-08-12 Pfizer, Inc. Lawsonia intracellularis proteins, and related methods and materials
JP2004529854A (ja) * 2000-09-29 2004-09-30 アリゾナ・ボード・オブ・リージエンツ・オン・ビハーフ・オブ・ザ・ユニバーシテイー・オブ・アリゾナ 増殖性回腸炎のための改善されたワクチン及びその作製と使用の方法
AUPR138100A0 (en) 2000-11-10 2000-12-07 Agriculture Victoria Services Pty Ltd Novel therapeutic compositions for treating infection by lawsonia spp
BR0114835A (pt) * 2000-11-10 2003-07-01 Agriculture Victoria Serv Pty Composições terapêuticas para tratamento de infecção por lawsonia spp
ES2360225T3 (es) * 2000-12-20 2011-06-02 Intervet International Bv Vacuna contra lawsonia intracellularis.
US20030087421A1 (en) * 2001-07-11 2003-05-08 Gebhart Connie J Lawsonia intracellularis
WO2004033631A2 (fr) * 2002-10-04 2004-04-22 Regents Of The University Of Minnesota Sequences d'acides nucleiques et polypeptidiques de lawsonia intracellularis et methodes d'utilisation
UA87665C2 (ru) * 2003-07-25 2009-08-10 Берингер Ингельхайм Ветмедика, Инк. Авирулентный изолят lawsonia intracellularis европейского происхождения, вакцина для иммунизации животных, применение заявленного авирулентного изолята как вакцины, способ получения вакцины, способ культивирования lawsonia intracellularis, способ диагностики пролиферативной энтеропатии свиней и способ получения антисыворотки к lawsonia intracellularis
ATE450545T1 (de) * 2003-09-12 2009-12-15 Intervet Int Bv Impfstoff mit lawsonia intracellularis- untereinheit
AU2004297018A1 (en) * 2003-12-09 2005-06-23 Intervet International B.V. Lawsonia intracellularis 26 KD subunit vaccine
KR20060134054A (ko) * 2004-01-22 2006-12-27 인터벳 인터내셔널 비.브이. 로소니아 인트라셀룰라리스 서브유닛 백신
EP1609870A1 (fr) * 2004-06-24 2005-12-28 Boehringer Ingelheim Vetmedica Gmbh Méthode du diagnostic de Lawsonia intracellularis
MY146476A (en) * 2004-06-24 2012-08-15 Boehringer Ingelheim Vetmed Method of diagnosing lawsonia intracellularis
US20060021536A1 (en) * 2004-07-30 2006-02-02 Limin Song Method for creating an absorbent article exhibiting a harmonic color scheme
KR100621882B1 (ko) * 2004-09-30 2006-09-19 건국대학교 산학협력단 돼지 증식성 회장염 감염돈에서 로소니아인트라셀룰라리스 균을 분리하는 방법
CA2586093A1 (fr) * 2004-11-24 2006-06-01 Pharmacia & Upjohn Company Llc Procedes de culture de lawsonia intracellularis
US20070212373A1 (en) * 2004-12-08 2007-09-13 Akzo Nobel N.V. Lawsonia Intracellularis 26 Kd Subunit Vaccine
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
US8398994B2 (en) * 2005-07-15 2013-03-19 Boehringer Ingelheim Vetmedica, Inc. Lawsonia vaccine and methods of use thereof
PL2371383T3 (pl) 2005-12-29 2016-01-29 Boehringer Ingelheim Vetmedica Inc Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
US20080226669A1 (en) 2005-12-29 2008-09-18 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
US8470336B2 (en) * 2006-05-25 2013-06-25 Boehringer Ingelheim Vetmedica, Inc. Vaccination of young animals against Lawsonia intracellularis infections
US20080241190A1 (en) * 2006-11-13 2008-10-02 Boehringer Ingelheim Vetmedica, Inc. Vaccination of horses against lawsonia intracellularis
WO2008073464A2 (fr) 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Procédé efficace de traitement du circovirus porcin et des infections par lawsonia intracellularis
ES2625460T5 (es) * 2006-12-15 2020-11-04 Boehringer Ingelheim Animal Health Usa Inc Tratamiento de cerdos seropositivos en anticuerpo anti-PCV2 con antígeno de PCV2
EP1941903A1 (fr) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxie et traitement du PRDC
EP1958644A1 (fr) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prévention et traitement du PCVD subclinique
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
US8398970B2 (en) 2007-09-17 2013-03-19 Boehringer Ingelheim Vetmedica, Inc. Method of preventing early Lawsonia intracellularis infections
WO2009049306A1 (fr) * 2007-10-12 2009-04-16 Pfizer Inc. Procédés de culture de lawsonia intracellularis
BRPI0821456A2 (pt) * 2007-12-31 2015-06-16 Boehring Ingelheim Vetmedica Inc Partícula similar à pcv2 orf2 com inserção de aminoácido estranho
EP2242511A4 (fr) 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed Compositions immunogènes de mycoplasma hyopneumoniae pcv2, et procédés de production de telles compositions
US20110033495A1 (en) * 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
TWI449533B (zh) 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
ES2534556T3 (es) * 2008-07-22 2015-04-24 Intervet International Bv Bacteria Lawsonia intracellularis de un nuevo serotipo, vacuna basada en esa bacteria, anticuerpos adecuados para diagnosticar el nuevo serotipo de Lawsonia intracellularis e hibridomas para producir dichos anticuerpos
US8142760B2 (en) * 2008-09-05 2012-03-27 Nathan Len Winkelman Vaccination for Lawsonia intracellularis
WO2011006880A1 (fr) * 2009-07-14 2011-01-20 Intervet International B.V. Propagation de lawsonia intracellularis
TWI627281B (zh) * 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
HUE032982T2 (hu) * 2009-11-09 2017-11-28 Intervet Int Bv Eljárás Lawsonia intracellularis baktériumok tenyésztésére tartósan fertõzött McCoy sejtekben
PL2938747T3 (pl) * 2012-12-28 2019-11-29 Boehringer Ingelheim Vetmedica Gmbh Sposób wytwarzania szczepionki przeciwko mykoplazmie
EP3049106A1 (fr) 2013-09-25 2016-08-03 Zoetis Services LLC Composition vaccinale divergente anti-pcv2b et ses procédés d'utilisation
DK3052516T3 (da) 2013-10-02 2020-03-23 Boehringer Ingelheim Animal Health Usa Inc PCV2-ORF2-proteinvariant og viruslignende partikler sammensat deraf
WO2016124620A1 (fr) 2015-02-04 2016-08-11 Intervet International B.V. Vaccin utile contre une infection sub-clinique par lawsonia chez un porc
JP2018504423A (ja) 2015-02-04 2018-02-15 インターベット インターナショナル ベー． フェー． 豚における無症候性ローソニア感染症に対する使用のためのワクチン
KR20180062468A (ko) * 2016-11-18 2018-06-11 녹십자수의약품(주) 신규한 로소니아 인트라셀룰라리스 균주 및 이의 용도
WO2019166362A1 (fr) 2018-02-28 2019-09-06 Boehringer Ingelheim Vetmedica Gmbh Procédé de réduction du scatole et/ou de l'indole chez les animaux
MX2023001024A (es) 2020-07-24 2023-02-15 Boehringer Ingelheim Animal Health Usa Inc Vacuna porcina combinada.
AU2022375120A1 (en) 2021-11-01 2024-04-11 Boehringer Ingelheim Vetmedica Gmbh Immunogenic gel compositions
WO2024068637A1 (fr) 2022-09-27 2024-04-04 Intervet International B.V. Procédé de culture de bactéries lawsonia intracellularis
WO2024260953A1 (fr) * 2023-06-23 2024-12-26 Intervet International B.V. Procédé de culture de bactéries lawsonia intracellularis
CN119185351B (zh) * 2024-09-25 2025-09-16 武汉轻工大学 Li0004蛋白靶点在制备抑制劳森菌感染细胞增殖的药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132597A (en) * 1976-06-09 1979-01-02 Ab Medipharm Method for cultivation of bacteria
US4237218A (en) * 1979-02-09 1980-12-02 Bio-Rad Laboratories, Inc. Micro-carrier cell culture
JPS5991879A (ja) * 1982-11-16 1984-05-26 Hideaki Yamada シユ−ドモナス属細菌の培養法
DK594084A (da) * 1984-12-12 1986-06-13 Novo Industri As Fremgangsmaade til stabilisering af extra-chromosomale elementer i bakterier under dyrkning
JPH0644865B2 (ja) * 1985-10-29 1994-06-15 三菱瓦斯化学株式会社 カンピロバクタ−属細菌の培養方法
US5338670A (en) * 1986-07-28 1994-08-16 The United States Of America As Represented By The Department Of Health And Human Services Production of bordetella pertussis toxin with a low concentration of iron
IT1227657B (it) * 1988-12-01 1991-04-23 Mini Ricerca Scient Tecnolog Antibiotici ab-021 e processo per la loro produzione
JPH0822221B2 (ja) * 1988-12-28 1996-03-06 日東化学工業株式会社 シュードモナス属細菌の培養法
JPH02308754A (ja) * 1989-05-24 1990-12-21 Yakult Honsha Co Ltd 乳発酵食品の製造法
US5296221A (en) * 1990-01-31 1994-03-22 Sani-Ei Sucrochemical Co., Ltd. Lactobacillus johnsonii ferm bp-2680 lactic acid bacteria preparations using the same and a process of manufacturing the preparations
DK0555366T3 (da) * 1990-11-01 2000-08-28 Univ Iowa State Res Found Inc Fremgangsmåde til bakteriel svækkelse og vaccine
SU1768637A1 (en) * 1990-12-04 1992-10-15 Inst Virusologii Im D I Ivanov Strain of human immunodeficient virus 1-type for preparation of diagnostic preparation
JP3043809B2 (ja) * 1991-11-15 2000-05-22 ファイザー・インコーポレイテッド グラム陰性菌ワクチン
DE4208785A1 (de) * 1992-03-19 1993-09-23 Degussa Verfahren zum auffinden von insertionselementen (is-elemente) oder transposonen
US5610059A (en) * 1992-11-09 1997-03-11 University Of Arizona Etiological agent for porcine enteritis

Also Published As

Publication number Publication date
KR19990022509A (ko) 1999-03-25
JP2008266340A (ja) 2008-11-06
KR100513481B1 (ko) 2006-01-27
ES2294620T3 (es) 2008-04-01
EP0843818A1 (fr) 1998-05-27
BG64292B1 (bg) 2004-08-31
ES2332587T3 (es) 2010-02-09
RU2005114739A (ru) 2006-11-20
RU2265849C2 (ru) 2005-12-10
DE69638016D1 (de) 2009-10-15
HK1010911A1 (en) 1999-07-02
EP1645567B1 (fr) 2007-09-12
WO1996039629A1 (fr) 1996-12-12
EP0843818A4 (fr) 2002-02-06
PT1645567E (pt) 2007-11-19
KR100758614B1 (ko) 2007-09-13
EP1645567B2 (fr) 2016-01-06
ES2173055T1 (es) 2002-10-16
EP0843818B1 (fr) 2005-02-09
RO118885B1 (ro) 2003-12-30
EP1403643B2 (fr) 2018-10-03
EP2199795B1 (fr) 2016-03-30
ATE373015T1 (de) 2007-09-15
EP1645567A1 (fr) 2006-04-12
DE69634334T2 (de) 2006-04-13
BG102130A (bg) 1998-09-30
PL189187B1 (pl) 2005-07-29
CZ295933B6 (cs) 2005-12-14
PL189250B1 (pl) 2005-07-29
KR20050048651A (ko) 2005-05-24
BR9608338B1 (pt) 2009-05-05
KR20050046741A (ko) 2005-05-18
BRPI9612938B1 (pt) 2010-07-27
PT1403643E (pt) 2009-10-08
RU2305707C2 (ru) 2007-09-10
PL187849B1 (pl) 2004-10-29
EP1655607A1 (fr) 2006-05-10
DE122007000102I1 (de) 2008-04-17
JP2007151554A (ja) 2007-06-21
PL187850B1 (pl) 2004-10-29
JP4263212B2 (ja) 2009-05-13
PL325872A1 (en) 1998-08-17
EP2199795A3 (fr) 2010-11-03
CZ389997A3 (cs) 1998-07-15
CA2222643A1 (fr) 1996-12-12
PT843818E (pt) 2005-04-29
BRPI9612938B8 (pt) 2017-09-12
AU717045B2 (en) 2000-03-16
ES2173055T3 (es) 2005-07-01
FR07C0071I1 (fr) 2008-01-02
JP2006061165A (ja) 2006-03-09
EP0843818B2 (fr) 2018-12-19
PL189286B1 (pl) 2005-07-29
NL300331I1 (nl) 2008-03-03
DE69637251T3 (de) 2016-06-02
DK1645567T4 (en) 2016-04-11
MX9709464A (es) 1998-06-30
HUP9900884A3 (en) 2001-01-29
FR07C0071I2 (fr) 2010-12-31
KR100544857B1 (ko) 2006-01-24
HU230199B1 (hu) 2015-10-28
DE69637251T2 (de) 2008-06-12
JP3920300B2 (ja) 2007-05-30
ES2294620T5 (es) 2016-03-23
DE69634334D1 (de) 2005-03-17
JP5078740B2 (ja) 2012-11-21
DE69637251D1 (de) 2007-10-25
KR20060129549A (ko) 2006-12-15
PL189287B1 (pl) 2005-07-29
HUP9900884A2 (hu) 1999-07-28
EP2199795A2 (fr) 2010-06-23
NL300331I2 (nl) 2008-07-01
AU6262796A (en) 1996-12-24
EP1655607B1 (fr) 2015-05-13
ATE441863T1 (de) 2009-09-15
JPH11507225A (ja) 1999-06-29
DE843818T1 (de) 2002-11-28
US5885823A (en) 1999-03-23
CA2222643C (fr) 2013-08-13
JP3765834B2 (ja) 2006-04-12
EP1403643A1 (fr) 2004-03-31
ATE289069T1 (de) 2005-02-15
DK0843818T3 (da) 2005-05-09
EP1403643B1 (fr) 2009-09-02
BR9608338A (pt) 1999-01-05
NZ319994A (en) 2000-01-28
DK1403643T3 (da) 2010-01-04
DK1645567T3 (da) 2007-11-26

Similar Documents

Publication Publication Date Title
LU91405I2 (fr) "Lawsonia intracellularis et ses dérivés pharmaceutiquement acceptables (Enterisol Ileitis)"
LU91673I2 (fr) "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
LU91205I2 (fr) Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)
LU91163I2 (fr) Hydrobromure de darifénacine et ses dérivés pharmaceutiquement acceptables (EMSELEX.
LU91122I2 (fr) Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
LU91452I2 (fr) "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"
LU91655I2 (fr) Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®)
EP0738443A4 (fr) Architecture de temporisation d'interconnexion numerique multin ud integree
EP0719806A3 (fr) Composition d'un copolymère d'un cyclooléfine
EP0765166A4 (fr) Conjugues radiomarques d'annexine-galactose
TR199600499A2 (tr) S(+)-Etodolak'in oral formülasyonlari.
KR960003695U (ko) 남성용 팬티
TR199600471A2 (tr) COCCIDIOSIS'e karsi uygulanan yumurta ici asilama.
DK0821692T3 (da) Immunopotenserende inosinmonophosphat-5'-nukleotidasemodstandsdygtige derivater og anvendelser deraf
FR2738739B1 (fr) Prothese de genou unicondylienne du type dit "a glissement"
NO961404D0 (no) 4-indolylpiperazinyl-derivater
FR2713641B1 (fr) Dérivés de l'épi-épibatidine.
FI913548L (fi) Uppblaosbar och toembar dyna och med en saodan dyna foersett lyftdon.
FR2736937B1 (fr) Machine d'etirage-texturation par fausse torsion
AUPN542395A0 (en) Macca's magic sinkers
KR960038660U (ko) 브라운관의 반전이재기
EP0749778A3 (fr) Agent d'absorption
IT239125Y1 (it) Capo d'abbigliamento intimo perfezionato
FR2735986B3 (fr) Prolongateur d'haltere
KR970000413U (ko) 남성용 신체단련기